Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genasense with Fludarabine and Cyclophosphamide in Relapsed/Refractory CLL
NCT00024440Phase 3Completed
- Sponsor
- Genta Incorporated
- Start
- Jul 2001
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of oblimersen in chronic lymphocytic leukemia (CLL) (2 arms), sponsored by Genta Incorporated. Primary endpoint: Complete Response and Nodular Partial Response. Started Jul 2001; status: completed.
02
Drugs
oblimersen
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00024440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00024440.